Corona Remedies Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹1008 - ₹1062
- Lot size
- 14 shares
- Issue amount
- ₹655.37 cr
- Total subscription
- 144.49×
- Opens
- 8 Dec 2025
- Closes
- 10 Dec 2025
- Allotment
- 11 Dec 2025
- Listing
- 15 Dec 2025
Offer at a glance
Issue overview
- Issue size
- 61,71,102 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹14,112
- Fresh issue
- ₹0 cr
- Offer for sale
- ₹655.37 cr
- Registrar
- Bigshare Services Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹1,21,068
- Issue type
- Bookbuilding IPO
- Shares before issue
- 6,11,60,088
- Shares after issue
- 6,11,60,088
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 14 | ₹14,868 |
| sHNI | 14 | 196 | ₹2,08,152 |
| bHNI | 68 | 952 | ₹10,11,024 |
Share reservation
Subscription & GMP
Subscription by category
Reported 10 Dec 2025
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 1,52,827 | 37,92,248 |
| EMPLOYEES | 0 | 35,988 |
| HNIs(10L +) | 3,119 | 1,55,224 |
| HNIs (2-10L) | 1,559 | 2,49,992 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 129.75 | 38,119.37 |
| FIs | 0 | 0.81 |
| Others | 0 | 11.64 |
| RETAIL | 227.22 | 6,881.98 |
| HNIs 2+ | 32.46 | 5,427.21 |
| HNIs 10+ | 64.92 | 16,014.25 |
| EMPLOYEES | 6.16 | 95.89 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Jun-25 | Mar-25 | Mar-24 |
|---|---|---|---|
| EPS | 7.55 | 24.43 | 14.8 |
| ROE | 7.61 | 27.5 | 20.36 |
| ROCE | 11.28 | 41.32 | 31.19 |
| RONW | 20.5 | 24.65 | 18.84 |
| PRE IPO(PE) | 0 | 43.47 | 0 |
| POST IPO(PE) | 35.15 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Corona Remidies Limited | 0 | 0 | 0 | 99.14 | 24.65 | 24.43 |
| Abbott India Ltd | 45.17 | 0 | 0 | 1,992.14 | 33.41 | 665.62 |
| Alkem Laboratories Ltd | 31.39 | 0 | 0 | 1,002.37 | 18.07 | 181.11 |
| Eris Lifesciences Ltd | 25.85 | 0 | 0 | 209.73 | 12.21 | 25.85 |
| Glaxosmithkline Pharmaceuticals Ltd | 46.87 | 0 | 0 | 115.19 | 47.54 | 54.76 |
| J.b.chemicals & Pharmaceuticals Ltd | 42.45 | 0 | 0 | 220.88 | 19.21 | 42.45 |
| Mankind Pharma Limited | 45.77 | 0 | 0 | 352.51 | 13.89 | 49.28 |
| Pfizer Ltd | 29.63 | 0 | 0 | 921.88 | 18.20 | 167.79 |
| Sanofi India Ltd | 24.47 | 0 | 0 | 373.68 | 48.05 | 179.46 |
| Torrent Pharmaceuticals Ltd | 65.91 | 0 | 0 | 224.28 | 25.18 | 56.47 |
Company information
Company profile
Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas including women’s healthcare, cardiology, pain management, urology, and multispecialty segments. As of December 2024, its portfolio includes 67 brands covering women’s health, cardio-diabetic care, pain relief, urology, and multispecialty products such as vitamins, minerals, nutrition, gastrointestinal, and respiratory medications. The company has established a strong pan-India presence with 2,598 medical representatives across 22 states, ensuring deep engagement with healthcare professionals and hospitals. It operates two manufacturing facilities in Gujarat, supporting its production and quality-focused growth strategy in the Indian Pharmaceutical Market.
Strengths
- Leading Market Growth Position: The company is the second fastest-growing among the top 30 pharmaceutical players (MAT 2022–2025), well-positioned to benefit from India’s expanding pharmaceutical demand.
- Diversified & Scalable Product Range: Successfully developing multiple “engine brands” across key therapy areas—women’s health, cardio-diabetic, pain, and urology—supports sustainable long-term growth.
- Extensive Pan-India Sales Network: A broad national sales and marketing network targeting specialist doctors and mid-income patients drives prescription growth above the overall market rate.
Risk factors
- High Reliance on Key Therapy Areas: More than 60% of revenue is generated from women’s health, cardio-diabetic, and pain management segments; underperformance or intensified competition in these areas may hinder growth.
- Concentration in Major Engine Brands: 27 primary “engine brands” account for over 70% of domestic sales; any decline in top brands like B-29 or Myoril could significantly impact performance.
- Dependence on Indian Market: Over 96% of revenue comes from India; weak domestic demand or delays in international expansion could adversely affect financial stability.
Promoters
Dr. Kirtikumar Laxmidas Mehta
Niravkumar Kirtikumar Mehta
Ankur Kirtikumar Mehta
Registrar & documents
Lead manager
IIFL Capital Services Limited, Jm Financial Limited, Kotak Mahindra Capital Company
Registrar & contacts
Bigshare Services Private Limited
[email protected]Official registrar portal ↗Check allotment status on registrar →Registered office
CORONA House, C – Mondeal Business Park Near Gurudwara S. G. Highway Thaltej Ahmedabad, Gujarat, 380059
+91 79 4023 3000
[email protected]Company website ↗Frequently Asked Questions
What is Corona Remedies IPO GMP today?
As of today, Corona Remedies IPO Grey Market Premium (GMP) is reported at +₹344 per share. Based on the upper price band of ₹1,062, the estimated listing price is ₹1,406 (+32.4% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.
What is the lot size and minimum investment for Corona Remedies IPO?
The minimum bid lot size for Corona Remedies IPO is 14 shares. At the cut-off price of ₹1,062 per share, retail investors need a minimum application amount of ₹14,868 per lot. Retail applicants can apply for a maximum of 13 lots (up to ₹2,00,000).
When will Corona Remedies IPO allotment status be announced?
The allotment status for Corona Remedies IPO is scheduled to be finalized on 11 Dec 2025. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Bigshare Services Private Limited's official portal or via BSE/NSE allotment portals.
How can I check Corona Remedies IPO allotment status online by PAN?
To check Corona Remedies IPO allotment status: 1) Visit the registrar portal (Bigshare Services Private Limited) or the BSE IPO allotment page. 2) Select 'Corona Remedies Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Explore More IPO Analysis & Live Tools
Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.